Vertex Reports First-Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Vertex Pharma (VRTX) Tops Q1 EPS by 16c, Revenues Beat; Affirms FY19 Revenue Guidance Below Consensus
April 30, 2019 4:04 PM EDTVertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $1.14, $0.16 better than the analyst estimate of $0.98. Revenue for the quarter came in at $857 million versus the consensus estimate of $850.93 million.
First-quarter 2019 product revenues of $857 million, a 34% increase compared to $638 million in 2018-First-quarter 2019 GAAP operating income increased 115% to $277 million;... More